Videtic, G M <br/><br/>
Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)   
 - 249-58 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0169-5002 
<br/><br/><label>Standard No.: </label>10.1016/s0169-5002(00)00240-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Small Cell--drug therapy<br/>Cyclophosphamide--therapeutic use<br/>Doxorubicin--therapeutic use<br/>Epirubicin--therapeutic use<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Remission Induction<br/>Survival Rate<br/>Treatment Failure<br/>Vincristine--therapeutic use